ADVANCES IN ETHER PHOSPHOLIPIDS TREATMENT OF CANCER

[1] ALUNNIBISTOCCHI G, 1990, FARMACO, V45, P499

[2] Andreesen R, 1988, Prog Biochem Pharmacol, V22, P118

[3] ANDREESEN R, 1988, NEW TRENDS LIPID MED, V1, P16

[4] AN ANTAGONIST TO PLATELET ACTIVATING FACTOR COUNTERACTS THE TUMORICIDAL ACTION OF ALKYL LYSOPHOSPHOLIPIDS [J]. BIOCHEMICAL PHARMACOLOGY, 1989, 38 (02) : 374 - 377

[5] BAZILL GW, 1990, CANCER RES, V50, P7505

[6] BERDEL WE, 1987, ANTICANCER RES, V7, P1181

[7] MEMBRANE-INTERACTIVE LIPIDS AS EXPERIMENTAL ANTICANCER DRUGS [J]. BRITISH JOURNAL OF CANCER, 1991, 64 (02) : 208 - 211

[8] BERDEL WE, 1992, ONKOLOGIE, V15, P238

[9] BERDEL WE, 1985, PHOSPHOLIPIDS CELLUL, V2, P41

[10] BERDEL WE, 1987, PLATELET ACTIVATING, P449

[1] ALUNNIBISTOCCHI G, 1990, FARMACO, V45, P499

[2] Andreesen R, 1988, Prog Biochem Pharmacol, V22, P118

[3] ANDREESEN R, 1988, NEW TRENDS LIPID MED, V1, P16

[4] AN ANTAGONIST TO PLATELET ACTIVATING FACTOR COUNTERACTS THE TUMORICIDAL ACTION OF ALKYL LYSOPHOSPHOLIPIDS [J]. BIOCHEMICAL PHARMACOLOGY, 1989, 38 (02) : 374 - 377

[5] BAZILL GW, 1990, CANCER RES, V50, P7505

[6] BERDEL WE, 1987, ANTICANCER RES, V7, P1181

[7] MEMBRANE-INTERACTIVE LIPIDS AS EXPERIMENTAL ANTICANCER DRUGS [J]. BRITISH JOURNAL OF CANCER, 1991, 64 (02) : 208 - 211

[8] BERDEL WE, 1992, ONKOLOGIE, V15, P238

[9] BERDEL WE, 1985, PHOSPHOLIPIDS CELLUL, V2, P41

[10] BERDEL WE, 1987, PLATELET ACTIVATING, P449